LEXICON
No.125 September 10, 2012

GPMSP (good post-marketing surveillance practice)
医薬品の市販後調査の基準
GPSP (good post-marketing study practice)
医薬品の製造販売後の調査及び試験の実施の基準
GVP (good vigilance practice)
医薬品、医薬部外品、化粧品及び医療機器の製造販売後安全管理の基準

The amended Pharmaceutical Affairs Law (PAL; 薬事法), which went into full effect on April 1, 2005, divided post-marketing surveillance (PMS; 市販後調査), which had been conducted in accordance with the GPMSP (good post-marketing surveillance practice) standards (医薬品の市販後調査の基準), into 1) post-marketing drug...

To read the full story

LEXICON

By Takashi Ohama

The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…